Percheron Therapeutics Limited

ASX:PER Stock Report

Market Cap: AU$7.4m

Percheron Therapeutics Valuation

Is PER undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PER when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PER's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PER's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PER?

Key metric: As PER is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PER. This is calculated by dividing PER's market cap by their current revenue.
What is PER's PS Ratio?
PS Ratio2.5x
SalesAU$2.97m
Market CapAU$7.42m

Price to Sales Ratio vs Peers

How does PER's PS Ratio compare to its peers?

The above table shows the PS ratio for PER vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
FRE Firebrick Pharma
4.3xn/aAU$11.8m
RNO Rhinomed
1.4xn/aAU$11.5m
ACR Acrux
1.9x34.0%AU$9.9m
EPN Epsilon Healthcare
1xn/aAU$7.2m
PER Percheron Therapeutics
2.5x42.1%AU$7.4m

Price-To-Sales vs Peers: PER is expensive based on its Price-To-Sales Ratio (2.5x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does PER's PS Ratio compare vs other companies in the AU Pharmaceuticals Industry?

17 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.4.3x49.8%
PER Percheron Therapeutics
 2.5x42.1%US$4.64m
MYX Mayne Pharma Group
1x9.3%US$241.07m
PBP Probiotec
1.1x6.7%US$160.13m
PER 2.5xIndustry Avg. 4.3xNo. of Companies17PS01224364860+
17 CompaniesEstimated GrowthMarket Cap
Industry Avg.4.3x36.9%
PER Percheron Therapeutics
 2.5x24.7%US$4.64m
No more companies

Price-To-Sales vs Industry: PER is good value based on its Price-To-Sales Ratio (2.5x) compared to the Australian Pharmaceuticals industry average (4.3x).

Price to Sales Ratio vs Fair Ratio

What is PER's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PER PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.5x
Fair PS Ratio6.4x

Price-To-Sales vs Fair Ratio: PER is good value based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (6.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PER forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.007
AU$0.09
+1,185.7%
125.7%AU$0.25AU$0.01n/a3
Dec ’25AU$0.074
AU$0.21
+183.8%
23.7%AU$0.25AU$0.14n/a3
Nov ’25AU$0.079
AU$0.22
+174.3%
25.7%AU$0.27AU$0.14n/a3
Oct ’25AU$0.10
AU$0.22
+116.7%
25.7%AU$0.27AU$0.14n/a3
Sep ’25AU$0.087
AU$0.22
+149.0%
25.7%AU$0.27AU$0.14n/a3
Aug ’25AU$0.071
AU$0.21
+200.5%
25.5%AU$0.27AU$0.14n/a3
Jul ’25AU$0.08
AU$0.25
+212.5%
8.0%AU$0.27AU$0.23n/a2
Jun ’25AU$0.081
AU$0.25
+208.6%
8.0%AU$0.27AU$0.23n/a2
May ’25AU$0.073
AU$0.25
+242.5%
8.0%AU$0.27AU$0.23n/a2
Apr ’25AU$0.083
AU$0.25
+201.2%
8.0%AU$0.27AU$0.23n/a2
Mar ’25AU$0.088
AU$0.25
+184.1%
8.0%AU$0.27AU$0.23n/a2
Feb ’25AU$0.058
AU$0.25
+331.0%
8.0%AU$0.27AU$0.23n/a2
Jan ’25AU$0.059
AU$0.27
+349.2%
13.2%AU$0.30AU$0.23n/a2
Dec ’24AU$0.06
AU$0.27
+341.7%
13.2%AU$0.30AU$0.23AU$0.0742
Nov ’24AU$0.057
AU$0.27
+364.9%
13.2%AU$0.30AU$0.23AU$0.0792
Oct ’24AU$0.068
AU$0.27
+289.7%
13.2%AU$0.30AU$0.23AU$0.102
Sep ’24AU$0.059
AU$0.27
+349.2%
13.2%AU$0.30AU$0.23AU$0.0872
Aug ’24AU$0.054
AU$0.28
+413.8%
7.1%AU$0.30AU$0.26AU$0.0712
Jul ’24AU$0.059
AU$0.31
+425.4%
16.1%AU$0.36AU$0.26AU$0.082
Jun ’24AU$0.06
AU$0.31
+416.7%
16.1%AU$0.36AU$0.26AU$0.0812
May ’24AU$0.075
AU$0.31
+313.3%
16.1%AU$0.36AU$0.26AU$0.0732
Apr ’24AU$0.089
AU$0.31
+248.3%
16.1%AU$0.36AU$0.26AU$0.0832
Mar ’24AU$0.095
AU$0.31
+226.3%
16.1%AU$0.36AU$0.26AU$0.0882
Feb ’24AU$0.088
AU$0.31
+252.3%
16.1%AU$0.36AU$0.26AU$0.0582
Jan ’24AU$0.097
AU$0.31
+219.6%
16.1%AU$0.36AU$0.26AU$0.0592
Dec ’23AU$0.087
AU$0.31
+256.3%
16.1%AU$0.36AU$0.26AU$0.062

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:56
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Percheron Therapeutics Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John HesterBell Potter
Iain WilkieMorgans Financial Limited
Dr StoreyWilsons Advisory and Stockbroking Ltd.